One of the key issues during adjuvant treatments is ensuring that patients have a worthwhile health-related quality of life (HRQOL). We compared short-term HRQOL in Turkish patients with operable breast cancer receiving EC or FEC as adjuvant chemotherapy. Eligible patients (n=60) with 
Given the timing required by its use, adjuvant therapy requires the patient to absorb complex medical data and make challenging trade-offs shortly after initial diagnosis.
However, many women are unprepared or unable to optimize adjuvant treatment decisions while experiencing the shock and dismay that often follow the confirmation of an invasive breast cancer diagnosis. Each woman needs to know the facts and circumstances of her own case and to fully understand the benefits and risks of adjuvant therapy. Only then can she, with her medical team, choose those therapies that will maximize her benefit as a patient and as a survivor in all aspects of her life, over both the short and longer term. So, one of the key issues in treatment of breast cancer is ensuring that patients have a worthwhile health-related quality of life. Moreover, the introduction of patients' points of view is considered a further step towards a more comprehensive humanistic approach to cancer treatment (12, 13) .
In recent years, more and more attention is being paid to quality of survival during and following treatment of cancers in addition to quantity of survival indices (14) . Our purpose was to compare short-term HRQOL in
Turkish patients with operable breast cancer receiving the combination of EC or FEC as adjuvant chemotherapy.
PATIENTS AND METHODS
After the approval of local ethical committee, between Table 3 and figure 1 show patients' mean scores for those variables that varied over time from patients with repeated questionnaires. In both groups, selected aspects of HRQOL were impaired over time significantly, with decreased physical and social/family activities and impaired psychology; however significant improvements in all these aspects were seen after the end of treatments. Table 4 and figure 2 illustrate the extent of anxiety and depressive symptoms by STAI and BDI, respectively. The anxiety scores were similar in both groups; but there were statistically significant difference between depression scores in Group I (favorable) and Group II (unfavorable) (p=0.002). Multiple regression analysis indicated that type of operation (MRM) and marital status (being married) were the factors affecting the depression scores (p=0.009 and p=0.022, respectively).
In the present study, age at time of diagnosis, education, type and adverse effects of chemotherapy had no impact on quality-of-life, depression and anxiety scores. The principal finding of this research is that MRM and married patients had poor quality of life due to depression.
Neither type and adverse effects of chemotherapy regimen nor age and education affected quality of life and psychometric scores. Quality of life studies following breastconserving therapy (BCT) or mastectomy has revealed that mastectomy patients had significantly lower body image, role, and sexual functioning scores and their lives were also more disrupted than BCT patients. In one study, mastectomy patients felt more self-conscious and ashamed of their body. In a more recent study, anxiety, depression, and self-esteem were also worse for mastectomy patients (27, 28) . So QOL was found to be useful for clinical decisionmaking processes during local treatment investigations. In conclusion, continued monitoring and clinical interventions to address common symptoms associated with diagnosis and treatment should be considered to improve physical and emotional functioning before, during and after the primary treatment for breast cancer.
